Eight years after a landmark buyout, Sanofi agrees to pay aggrieved Genzyme shareholders $315M to settle foot-dragging claims
Sanofi’s $20 billion deal to buy Genzyme in early 2011 qualifies as one of the smartest M&A pacts in industry history, netting a blockbuster MS drug franchise that still delivers billions to the pharma giant.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
